Stockscreener 앱 받기
1.41
0.71%
0.01
시간 외 거래:
1.42
0.01
+0.71%
전일 마감가:
$1.40
열려 있는:
$1.41
하루 거래량:
588.57K
Relative Volume:
0.64
시가총액:
$101.71M
수익:
-
순이익/손실:
$-292.19M
주가수익비율:
-0.3106
EPS:
-4.54
순현금흐름:
$-208.41M
1주 성능:
+0.00%
1개월 성능:
+6.02%
6개월 성능:
-34.72%
1년 성능:
-53.31%
1일 변동 폭
$1.36
$1.42
1주일 범위
$1.35
$1.5499
52주 변동 폭
$1.01
$5.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
명칭
Zentalis Pharmaceuticals Inc
전화
(858) 263-4333
주소
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.41 | 103.88M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-12 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2024-06-20 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-06-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2024-06-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 개시 | Cowen | Outperform |
| 2022-04-06 | 개시 | Wells Fargo | Overweight |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-29 | 개시 | Oppenheimer | Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-01-20 | 개시 | Wedbush | Outperform |
| 2020-09-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 개시 | H.C. Wainwright | Buy |
| 2020-04-28 | 개시 | Guggenheim | Buy |
| 2020-04-28 | 개시 | Jefferies | Buy |
| 2020-04-28 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 개시 | SVB Leerink | Outperform |
모두보기
Zentalis Pharmaceuticals Inc 주식(ZNTL)의 최신 뉴스
Published on: 2025-08-12 08:15:52 - Newser
Is Zentalis Pharmaceuticals Inc. stock a smart retirement pickROI Focused Stock Opportunities - mustnews.co.kr
Can a trend reversal in Zentalis Pharmaceuticals Inc. lead to recoveryFree Top Gaining Picks With Entry Signals - Newser
How to integrate Zentalis Pharmaceuticals Inc. into portfolio analysis toolsTrade Setup Builder with Custom Alerts - Newser
Custom watchlist performance reports with Zentalis Pharmaceuticals Inc.Price Spike Prediction for Active Traders - Newser
Analyzing recovery setups for Zentalis Pharmaceuticals Inc. investorsFree Swing Trading Plan With Smart Signals - Newser
Using economic indicators to assess Zentalis Pharmaceuticals Inc. potentialFree Confirmed Setup With Expert Accuracy - Newser
Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings - Defense World
Equities Analysts Offer Predictions for ZNTL Q3 Earnings - Defense World
Zentalis Pharmaceuticals Inc. stock outlook for YEARSecure Buy Strategy Based on Risk Parameters - Newser
Applying Wyckoff theory to Zentalis Pharmaceuticals Inc. stockFree Alert Feed for Momentum Based Picks - Newser
When is the best time to exit Zentalis Pharmaceuticals Inc.Predictive AI Signals for Short-Term Trading - Newser
Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold - Defense World
Why Zentalis Pharmaceuticals Inc. stock attracts strong analyst attentionFree Trend Analysis for Safer Trades - Newser
Zentalis price target lowered to $5 from $6 at Wells Fargo - TipRanks
ZNTL: Wells Fargo Adjusts Price Target, Maintains Rating | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism - TipRanks
Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals - TipRanks
Zentalis Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sentiment analysis tools applied to Zentalis Pharmaceuticals Inc.Free Growth Focused Entry Plan Suggestions - Newser
Zentalis Pharmaceuticals Reports Improved Financial Results - TipRanks
Zentalis (ZNTL) Q2 Loss Narrows 70% - The Motley Fool
Zentalis (ZNTL) Q2 Loss Narrows 70% - AOL.com
Zentalis Pharmaceuticals: Navigating the Crossroads of Innovation and Financial Prudence - AInvest
Zentalis Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress - GlobeNewswire
Zentalis Advances Revolutionary Ovarian Cancer Drug with $303M War Chest, FDA Fast-Track Potential - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
51,061 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Bought by Universal Beteiligungs und Servicegesellschaft mbH - Defense World
Real time social sentiment graph for Zentalis Pharmaceuticals Inc.Free Portfolio Diversification Stock Ideas - Newser
Zentalis Pharmaceuticals Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
When is Zentalis Pharmaceuticals Inc. stock expected to show significant growthSkyrocketing profit margins - Jammu Links News
What is the risk reward ratio of investing in Zentalis Pharmaceuticals Inc. stockHigh-octane financial growth - Jammu Links News
Is Zentalis Pharmaceuticals Inc. stock overvalued or undervaluedDiscover stock picks with superior returns - Jammu Links News
What makes Zentalis Pharmaceuticals Inc. stock price move sharplyGet daily updates on promising stocks - Jammu Links News
Should I hold or sell Zentalis Pharmaceuticals Inc. stock in 2025Stay informed with daily expert analysis - Jammu Links News
What are analysts’ price targets for Zentalis Pharmaceuticals Inc. in the next 12 monthsFree Wealth Management Insights - Jammu Links News
Zentalis Pharmaceuticals Inc (ZNTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Zentalis Pharmaceuticals Inc 주식 (ZNTL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
0.91%
3.06%
자본화:
|
볼륨(24시간):